Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event
- PMID: 1608936
- PMCID: PMC49276
- DOI: 10.1073/pnas.89.12.5286
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event
Abstract
A series of bicyclams have been shown to be potent and selective inhibitors of human immunodeficiency virus (HIV). The compounds are inhibitory to the replication of various HIV-1 and HIV-2 strains in various human T-cell systems, including peripheral blood lymphocytes, at 0.14-1.4 microM, without being toxic to the host cells at 2.2 mM. The bicyclam JM2763 is active against 3'-azido-3'-deoxythymidine (zidovudine; AZT)-resistant HIV-1 strains and acts additively with AZT. Mechanism of action studies revealed that the bicyclams (i.e., JM2763) interact with an early event of the retrovirus replicative cycle, which could be tentatively identified as a viral uncoating event.
Similar articles
-
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.Antimicrob Agents Chemother. 1994 Apr;38(4):668-74. doi: 10.1128/AAC.38.4.668. Antimicrob Agents Chemother. 1994. PMID: 7913308 Free PMC article.
-
The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.J Virol. 1996 Feb;70(2):689-96. doi: 10.1128/JVI.70.2.689-696.1996. J Virol. 1996. PMID: 8551604 Free PMC article.
-
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams.J Med Chem. 1996 Jan 5;39(1):109-19. doi: 10.1021/jm950584t. J Med Chem. 1996. PMID: 8568797
-
HIV proteinase inhibitors.Biochem Soc Trans. 1992 May;20(2):513-6. doi: 10.1042/bst0200513. Biochem Soc Trans. 1992. PMID: 1397651 Review. No abstract available.
-
Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy.Cancer Invest. 1992;10(2):143-53. doi: 10.3109/07357909209032775. Cancer Invest. 1992. PMID: 1551024 Review.
Cited by
-
Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.Curr Top Med Chem. 2012;12(24):2727-40. doi: 10.2174/1568026611212240003. Curr Top Med Chem. 2012. PMID: 23368099 Free PMC article.
-
Chemokines as molecular targets for therapeutic intervention.J Clin Immunol. 1999 Sep;19(5):280-92. doi: 10.1023/a:1020587407535. J Clin Immunol. 1999. PMID: 10535604 Free PMC article. Review.
-
Physiology and pharmacology of plerixafor.Transfus Med Hemother. 2013 Aug;40(4):237-45. doi: 10.1159/000354132. Epub 2013 Jul 19. Transfus Med Hemother. 2013. PMID: 24179472 Free PMC article. Review.
-
Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Curr Top Med Chem. 2014;14(13):1574-89. doi: 10.2174/1568026614666140827143541. Curr Top Med Chem. 2014. PMID: 25159167 Free PMC article. Review.
-
Imaging HIV-1 Nuclear Import, Uncoating, and Proviral Transcription.Methods Mol Biol. 2024;2807:15-30. doi: 10.1007/978-1-0716-3862-0_2. Methods Mol Biol. 2024. PMID: 38743218
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources